JPWO2022154116A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2022154116A5
JPWO2022154116A5 JP2022575662A JP2022575662A JPWO2022154116A5 JP WO2022154116 A5 JPWO2022154116 A5 JP WO2022154116A5 JP 2022575662 A JP2022575662 A JP 2022575662A JP 2022575662 A JP2022575662 A JP 2022575662A JP WO2022154116 A5 JPWO2022154116 A5 JP WO2022154116A5
Authority
JP
Japan
Prior art keywords
group
affinity peptide
amino acid
linker
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022575662A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022154116A1 (https=
JP7687350B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2022/001358 external-priority patent/WO2022154116A1/ja
Publication of JPWO2022154116A1 publication Critical patent/JPWO2022154116A1/ja
Publication of JPWO2022154116A5 publication Critical patent/JPWO2022154116A5/ja
Priority to JP2025085873A priority Critical patent/JP2025124732A/ja
Application granted granted Critical
Publication of JP7687350B2 publication Critical patent/JP7687350B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022575662A 2021-01-18 2022-01-17 化合物またはその塩、およびそれらにより得られる抗体 Active JP7687350B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025085873A JP2025124732A (ja) 2021-01-18 2025-05-22 化合物またはその塩、およびそれらにより得られる抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021005762 2021-01-18
JP2021005762 2021-01-18
PCT/JP2022/001358 WO2022154116A1 (ja) 2021-01-18 2022-01-17 化合物またはその塩、およびそれらにより得られる抗体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025085873A Division JP2025124732A (ja) 2021-01-18 2025-05-22 化合物またはその塩、およびそれらにより得られる抗体

Publications (3)

Publication Number Publication Date
JPWO2022154116A1 JPWO2022154116A1 (https=) 2022-07-21
JPWO2022154116A5 true JPWO2022154116A5 (https=) 2025-01-27
JP7687350B2 JP7687350B2 (ja) 2025-06-03

Family

ID=82448186

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022575662A Active JP7687350B2 (ja) 2021-01-18 2022-01-17 化合物またはその塩、およびそれらにより得られる抗体
JP2025085873A Pending JP2025124732A (ja) 2021-01-18 2025-05-22 化合物またはその塩、およびそれらにより得られる抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025085873A Pending JP2025124732A (ja) 2021-01-18 2025-05-22 化合物またはその塩、およびそれらにより得られる抗体

Country Status (8)

Country Link
US (1) US20240000965A1 (https=)
EP (1) EP4279500A4 (https=)
JP (2) JP7687350B2 (https=)
KR (1) KR20230133294A (https=)
CN (1) CN116829573A (https=)
AU (1) AU2022208654B2 (https=)
CA (1) CA3208296A1 (https=)
WO (1) WO2022154116A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2020090979A1 (ja) * 2018-10-31 2021-09-24 味の素株式会社 抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
WO2023234416A1 (ja) 2022-06-02 2023-12-07 味の素株式会社 親和性物質、化合物、抗体およびそれらの塩

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL106992A (en) 1988-02-11 1994-06-24 Bristol Myers Squibb Co Acylhydrazone derivatives of anthracycline and methods for their preparation
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
DK0871490T3 (da) 1995-12-22 2003-07-07 Bristol Myers Squibb Co Forgrenede hydrazonlinkere
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
WO2004043493A1 (en) 2002-11-14 2004-05-27 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
EP2478912B1 (en) 2003-11-06 2016-08-31 Seattle Genetics, Inc. Auristatin conjugates with anti-HER2 or anti-CD22 antibodies and their use in therapy
DE102004026304B3 (de) 2004-05-28 2005-08-25 Atlas Elektronik Gmbh Prüfverfahren für ein Verfahren zur passiven Gewinnung von Zielparamentern
JP5827769B1 (ja) 2015-03-27 2015-12-02 義徳 川窪 掃除装置
ES3058443T3 (es) * 2015-05-20 2026-03-10 Univ Kagoshima Modificación específica de anticuerpo con péptido de unión a IgG
AU2018259856B2 (en) * 2017-04-28 2025-05-01 Ajinomoto Co., Inc. Compound having substance that has affinity for soluble protein, cleavable moiety, and reactive group, or salt thereof
JPWO2019240288A1 (ja) 2018-06-14 2021-07-26 味の素株式会社 抗体に対する親和性物質、および生体直交性官能基を有する化合物またはその塩
KR102921757B1 (ko) 2018-06-14 2026-02-03 아지노모토 가부시키가이샤 항체에 대한 친화성 물질, 절단성 부분 및 반응성기를 갖는 화합물 또는 이의 염
WO2020009165A1 (ja) 2018-07-03 2020-01-09 味の素株式会社 修飾抗体およびその製造方法
JP6581254B1 (ja) 2018-07-09 2019-09-25 セイコーソリューションズ株式会社 クロック調整装置及びプログラム
JP6677281B2 (ja) 2018-08-23 2020-04-08 ブラザー工業株式会社 インクジェット記録装置、及びプログラム
JPWO2020090979A1 (ja) 2018-10-31 2021-09-24 味の素株式会社 抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
JP7110955B2 (ja) 2018-12-04 2022-08-02 トヨタ自動車株式会社 インホイールモータ

Similar Documents

Publication Publication Date Title
JPWO2022154116A5 (https=)
JP2020513019A5 (https=)
JP2020519643A5 (https=)
JP2023052910A5 (https=)
RU2010116152A (ru) Антитело против рецептора il-6
JPWO2022191283A5 (https=)
RU2010136029A (ru) Композиция, содержащая антитело, которое связывается с доменом ii her2, и его кислые варианты
AR040046A1 (es) Anticuerpo neutralizante humano anti-igfr
Ishida et al. Highly effective binding of phosphomonoester with neutral cyclic peptides which include a non-natural amino acid
Kuby et al. Studies on adenosine triphosphate transphosphorylases. Amino acid sequence of rabbit muscle ATP-AMP transphosphorylase
RU2001119328A (ru) Применение металлоорганического соединения для защиты и/или усиления кератиновых материалов и способ обработки
JP2011505146A5 (https=)
JP2020506685A5 (https=)
JP2019512500A5 (https=)
JP2009529509A5 (https=)
JP2019506140A5 (https=)
JPWO2023234416A5 (https=)
CA2382035C (fr) Composes synthetiques portant deux epitopes pour immunodosages
Steiner et al. Crystallizable human myeloma protein Dob has a hinge-region deletion
JP2006503088A5 (https=)
Ottl et al. A new strategy for regioselective interstrand disulfide bridging of multiple cysteine peptides
JP2022514348A5 (https=)
Inman et al. Synthesis of N. alpha.-(tert-butoxycarbonyl)-N. epsilon.-[N-(bromoacetyl)-. beta.-alanyl]-L-lysine: Its use in peptide synthesis for placing a bromoacetyl cross-linking function at any desired sequence position
Wade et al. Use of thiazolidine-mediated ligation for site specific biotinylation of mouse EGF for biosensor immobilisation
JPWO2022154127A5 (https=)